

TABLE OF CONTENTS

October 12, 2009

No. 2159

BUSINESS

- 1 Mediceo to Further Cut Distribution Costs
2 **NEW PRODUCTS**
- Novartis Launches Rasilez, 1st Antihypertensive with New MOA in 11 Years
- Eli Lilly Japan: Alimta Injection 100 mg
3 Ajinomoto Pharm. Aims at Sales of ¥100 Bil. in 5 Years

- 3 Abbott to Acquire Solvay's Pharma Business
4 Teijin Pharma Pursues Synergism between Drugs and Homecare Business

4 BUSINESS NEWS IN BRIEF

- Kyorin Licenses Uritos to Eisai in China
- Takeda to Set Up 4 Commercial Subsidiaries to Cover 7 Countries
- Bayer, Genzyme Start Copromoting Fludara
- Hisamitsu: Sales of Mohrus Tape Up 6.3%
- Astellas Files Lawsuit against Teva in the US
- Customs to Ban Import of Counterfeit Botox Products
- CMIC to Enhance Medidata EDC Services in Japan
- Quintiles to Hire 3,000 Contract MRs by 2015

6 TOPICS

- MTPC Recalls Arofuto
- Taiyo Recalls Famotidine Generic due to Deviations from Approved Specifications

REGULATORY

- 8 Japan's First DPP-4 Inhibitor Sitagliptin to Be Approved
8 Eisai Applies for Non-Erosive GERD in Japan as Additional Indication for Pariet
9 Eisai, Abbott Japan Apply for Humira for Crohn's Disease
9 Parliamentary Secretary Shinya Adachi to Evaluate *Chuikyo* Membership
10 **REGULATORY NEWS IN BRIEF**
- Application Filed for Approval of HP Eradication for 3 Diseases
- Seikagaku Applies for Supartz for Shoulder Osteoarthritis in the US
- Roche Applied for Inhibition of Joint Damage for Actemra in RA in Europe
- Xeloda Approved for XELOX Therapy: Chugai
- FDA Calls Attention to Pancreatitis Reported in Januvia-Treated Patients
- Gardasil Recommended for Approval by FDA for Boys and Men: Merck
- Cervarix Receives Favourable Recommendation by FDA: GSK

R&D

- 12 Astellas Concentrates Drug Discovery Functions in Tsukuba
12 Eisai Ties Up with DNDi for Chagas Disease
13 New Antibody Drugs for Cancer Highlighted at JCA Annual Meeting

- 13 *Koroshio* to Support Development of 12 Unapproved Drugs

14 R&D NEWS IN BRIEF

- BI Concludes PIII Program for Linagliptin
- QAB149 Improves Lung Function More Effectively than Spiriva: Novartis

COMMENTARY

- 16 How Not to License a Drug into Japan

SELF-MEDICATION

17 SELF-MEDICATION NEWS IN BRIEF

- Switch OTC Drugs Are Major Business Driver: SSP

GENERICS

- 18 Dr Hayakawa Calls For Flexible Applications of Guidance on Biosimilars

18 GENERICS NEWS IN BRIEF

- Mylan Confirms Efficacy, Safety of Merckmezin in Post-Marketing Survey
- Taiyo Starts Operating New Ophthalmic Solution Production Line

19 OPINION

- Why Negatives Never Make a Positive: Philip Carrigan

MEDICAL FACILITIES & NURSING CARE

- 20 *Koroshio* Proposes Distribution Scheme for Vaccines Made in Japan to Avoid Maldistribution

- 20 Flu Vaccines to Be Imported from GSK, Novartis

- 21 Gov't to Procure Flu Vaccines for 77 Million Persons

- Bills to Be Presented to Diet to Compensate for Health Problems

21 Survey

- 20% of Respondents Reluctant to Receive New-Type Flu Vaccines

22 Seminar

- Patients' Awareness of RA Treatment Insufficient: Prof. Yamamoto

22 MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

- Abolition of Healthcare System for Later-Stage Elderly Reconfirmed by Health Minister

- Visual Impairments Cost Japan ¥8.8 Trillion: JOA

MEDICAL DEVICES

23 MEDICAL DEVICE NEWS IN BRIEF

- HCV Antibody Detection Reagent Anti-HCV: Roche Diagnostics

- Endeavor Stent Reduces CV Risk More Significantly Than Paclitaxel-Eluting Stent: Medtronic

- Siemens Increases Investment Ratio in Mochida Siemens Medical System

23 ON THE MOVE

- Frank Florio Appointed Representative Director of BD Japan